# Chimera Clinical Advisory Board Charter (Indian Edition with FDA Annexure)

<div align="center">
<img src="https://img.shields.io/badge/-%F0%9F%A7%A0%20CHIMERA%20CLINICAL%20ADVISORY%20BOARD%20%F0%9F%A6%BE-6236FF?style=for-the-badge&labelColor=1A1A2E" alt="Chimera Clinical Advisory Board"/>

**Guiding the Future of Brain-Controlled Exoskeleton Technology for Home Use in India: A Make in India Initiative**

*Version 4.0 | Effective Date: April 2025*

[![CDSCO Compliance](https://img.shields.io/badge/CDSCO-Compliance%20Ready-green?style=flat-square)](https://cdsco.gov.in/opencms/opencms/en/Medical-Device-Diagnostics/)
[![FDA Compliance](https://img.shields.io/badge/FDA-Compliance%20Ready-green?style=flat-square&logo=data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAyNCAyNCI+PHBhdGggZD0iTTEyIDJDNi41IDIgMiA2LjUgMiAxMnM0LjUgMTAgMTAgMTAgMTAtNC41IDEwLTEwUzE3LjUgMiAxMiAyem0tMSAxNkg3di0yaDR2MnptNi40LTRINi42Yy0uOSAwLTEuNi0uNy0xLjYtMS42VjYuNkM1IDUuNyA1LjcgNSA2LjYgNWgxMC44Yy45IDAgMS42LjcgMS42IDEuNnY1LjhjMCAuOS0uNyAxLjYtMS42IDEuNnoiIGZpbGw9IndoaXRlIi8+PC9zdmc+)](https://www.fda.gov/medical-devices/digital-health-center-excellence/software-medical-device-samd)
[![ISO 14155](https://img.shields.io/badge/ISO%2014155-Clinical%20Investigation-blue?style=flat-square)](https://www.iso.org/standard/71690.html)
[![MDR 2017](https://img.shields.io/badge/MDR%202017-Compliant-blue?style=flat-square)](https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2022/m_device/Medical%20Devices%20Rules,%202017.pdf)
[![21 CFR Part 11](https://img.shields.io/badge/21%20CFR%20Part%2011-Compliant-blue?style=flat-square)](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=11)
[![Make in India](https://img.shields.io/badge/Make%20in%20India-Initiative-orange?style=flat-square)](https://www.makeinindia.com/)
[![BIS](https://img.shields.io/badge/BIS-IS%2023485-green?style=flat-square)](https://www.bis.gov.in/)

<img src="https://mermaid.ink/img/pako:eNptkstqwzAQRX9l0CqF-gtycdK0DRRCu2jooosgjUcxii0hTUIp_vfKjh-QeldzOVczI80JtJEEGbwSb8lYvCvNDZIVUXxA8t5ZJA_GklIRXdBYJGQvVkaUhLxGRaQ1qQiXZKSzpCJcxHmcx1mcx_9i5_uoIlzGeZzHeZzH-b_YRYRXcR7ncR7ncR7nMXZ-jirCdZzHeZzHeZzHeYyd36KK8C7O4zzO4zzO4zzGzh9RRfgY53Ee53Ee53EeY-fPqCL8ivM4j_M4j_M4j7HzLqoIf-I8zuM8zuM8zmPs_BtVhMc4j_M4j_M4j_MYO09RRXiK8ziP8ziP8ziPsXMa4SnO4zzO4zzO4zzGzlmEpziP8ziP8ziP8xg75xGe4jzO4zzO4zzOY-xcRHiK8ziP8ziP8ziPsXMZ4TnO4zzO4zzO4zzGzlWE5ziP8ziP8ziP8xg71xFe4jzO4zzO4zzOY-zcRHiJ8ziP8ziP8ziPsXMb4SXO4zzO4zzO4zzGzl2ElziP8ziP8ziP8xg79xFe4zzO4zzO4zzOY-w8RHiN8ziP8ziP8ziPsfMY4TXO4zzO4zzO4zzGzlOE1ziP8ziP8ziP8xg7zxFe4zzO4zzO4zzOY-y8RHiN8ziP8ziP8ziPsfMa4TXO4zzO4zzO4zzGzluE1ziP8ziP8ziP8xg77xFe4zzO4zzO4zzOY-x8RHiN8ziP8ziP8ziPsfMZ4TXO4zzO4zzO4zzGzleE1ziP8ziP8ziP8xg73xFe4zzO4zzO4zzOY-z8RHiN8ziP8ziP8ziPsfNfhNc4j_M4j_M4j_MYO_8DlnQFtQ" alt="Chimera Neural Interface System" width="300px" />
</div>

## 1. Executive Summary

The Chimera Clinical Advisory Board (CAB) is a cornerstone of our regulatory and clinical strategy, providing expert guidance for the development, validation, and market introduction of the Chimera brain-computer interface (BCI) controlled exoskeleton platform in India. This charter establishes a world-class advisory body comprising leading experts in neurology, rehabilitation medicine, neuroscience, bioethics, patient advocacy, regulatory affairs, and clinical research methodology with specific expertise in the Indian healthcare context.

As an Indian startup, Chimera is developing a revolutionary BCI-controlled exoskeleton designed specifically for home use without professional supervision after appropriate training. The CAB will play a critical role in ensuring that the Chimera platform meets the highest standards of clinical efficacy, safety, and ethical implementation while navigating the complex regulatory landscape for novel neurotechnology devices in India. Through strategic guidance on clinical trial design, CDSCO regulatory pathways, safety monitoring for home use, and technology assessment in Indian home environments, the CAB will accelerate our path to market while maximizing clinical impact and commercial success.

This charter defines the CAB's purpose, responsibilities, membership requirements, operational procedures, and governance structure, establishing a framework for leveraging expert insights to achieve our billion-dollar market potential in the Indian healthcare technology sector. The charter also includes an FDA annexure to support future global expansion while maintaining our primary focus on the Indian market.

## 2. Purpose and Scope

### 2.1 Mission Statement

The Chimera Clinical Advisory Board exists to ensure that our brain-controlled exoskeleton technology achieves optimal clinical outcomes, maintains the highest safety standards for unsupervised home use, and navigates Indian regulatory pathways efficiently while addressing ethical considerations in neurotechnology implementation within the Indian healthcare context.

### 2.2 Strategic Objectives

The CAB will support Chimera in achieving the following strategic objectives:

1. **Accelerate Regulatory Approval**: Provide expert guidance to optimize regulatory strategy and expedite CDSCO approval for home use medical devices
2. **Enhance Clinical Validation**: Design and oversee robust clinical studies in India that demonstrate safety and effectiveness in home environments
3. **Maximize Therapeutic Impact**: Identify optimal patient populations and clinical protocols to maximize therapeutic benefits in Indian healthcare settings
4. **Ensure Ethical Implementation**: Address neuroethical considerations and establish responsible use guidelines for the Indian context
5. **Support Market Adoption**: Develop strategies for clinical integration and reimbursement pathways within the Indian healthcare system
6. **Maintain Competitive Advantage**: Provide insights on emerging technologies and competitive positioning in the Indian market
7. **Optimize Home Use Safety**: Develop comprehensive protocols for safe home use without professional supervision
8. **Enable Global Expansion**: Provide guidance on international regulatory pathways while maintaining focus on Indian market priorities

### 2.3 Scope of Authority

The CAB serves in an advisory capacity to Chimera leadership with the following scope:

- Provides recommendations on clinical and regulatory strategy for the Indian market
- Reviews and advises on clinical study designs and protocols for studies conducted in India
- Evaluates safety data and recommends risk mitigation strategies for home use
- Offers guidance on ethical considerations and responsible implementation in the Indian context
- Advises on home use training protocols and safety monitoring systems
- Provides insights on international regulatory requirements for future expansion
- Does not have direct decision-making authority over company operations
- Cannot commit company resources without executive approval

## 3. Responsibilities

### 3.1 Clinical Strategy Development

#### 3.1.1 Clinical Trial Design and Oversight
- Develop comprehensive clinical development plan aligned with CDSCO requirements
- Design statistically rigorous clinical trial protocols with appropriate endpoints for the Indian population
- Recommend inclusion/exclusion criteria to optimize patient selection for home use
- Advise on site selection and investigator qualifications in India
- Review clinical study progress and interim results
- Recommend protocol modifications based on emerging data from Indian studies

#### 3.1.2 Outcome Measures and Endpoints
- Identify clinically meaningful primary and secondary endpoints relevant to the Indian population
- Recommend validated assessment tools and measurement techniques appropriate for the Indian context
- Advise on patient-reported outcome measures culturally adapted for India
- Develop strategies for long-term efficacy monitoring in home environments
- Guide development of novel outcome measures specific to BCI-controlled exoskeletons used at home

#### 3.1.3 Home Use Protocol Development
- Design optimal protocols for device calibration and patient training for home use
- Establish guidelines for therapy progression and intensity without professional supervision
- Develop comprehensive home use protocols specific to Indian home environments
- Create standards for patient and caregiver training and certification
- Recommend approaches for personalizing therapy to individual patients in home settings
- Develop remote monitoring protocols for unsupervised use

### 3.2 Regulatory Guidance

#### 3.2.1 Indian Regulatory Strategy
- Advise on optimal regulatory pathways under Medical Devices Rules, 2017
- Guide preparation for pre-submission meetings with CDSCO
- Review regulatory submissions for clinical content accuracy
- Provide insights on international regulatory approaches for potential expansion
- Advise on post-market surveillance requirements in India

#### 3.2.2 Documentation Review
- Review clinical sections of CDSCO regulatory submissions
- Evaluate clinical evidence summaries and clinical evaluation reports
- Assess benefit-risk analyses for regulatory purposes
- Review clinical validation protocols and reports for home use
- Provide expert opinions for regulatory responses to CDSCO

#### 3.2.3 Compliance Oversight
- Ensure clinical studies comply with Indian GCP requirements
- Advise on implementation of electronic records requirements for clinical data
- Guide compliance with human subject protection regulations in India
- Provide insights on evolving regulatory requirements for AI/ML in medical devices in India
- Advise on clinical aspects of quality system implementation under MDR 2017

#### 3.2.4 International Regulatory Considerations
- Provide guidance on FDA regulatory pathways (510(k), De Novo, PMA) for future expansion
- Advise on harmonization strategies between CDSCO and international requirements
- Identify key differences in clinical evidence requirements across markets
- Guide development of regulatory strategy that prioritizes Indian approval while enabling future global expansion
- Support preparation for international regulatory submissions when appropriate

### 3.3 Safety and Ethics Oversight

#### 3.3.1 Home Use Safety Monitoring
- Establish safety monitoring protocols for unsupervised home use
- Develop remote safety monitoring systems for home users
- Review adverse event reports and recommend responses
- Develop risk mitigation strategies for identified safety concerns in home environments
- Advise on post-market surveillance methodologies for home use devices
- Guide development of safety training materials for users and caregivers

#### 3.3.2 Ethical Framework Development
- Establish ethical guidelines for BCI technology implementation in the Indian context
- Address privacy concerns related to neural data collection under Indian data protection laws
- Develop protocols for informed consent in vulnerable populations
- Provide guidance on equitable access considerations in the Indian healthcare system
- Address potential psychological impacts of BCI technology in the Indian cultural context

#### 3.3.3 Risk Management for Home Use
- Review risk analysis documentation with focus on home use scenarios
- Advise on risk control implementation for unsupervised use
- Evaluate residual risk acceptability for home environments
- Guide benefit-risk determinations for home use without supervision
- Recommend approaches for communicating risks to users and caregivers in culturally appropriate ways

### 3.4 Technology Assessment

#### 3.4.1 Home Use Evaluation
- Assess technology performance in Indian home settings
- Evaluate user experience from patient and caregiver perspectives
- Identify opportunities for technology refinement for Indian home environments
- Compare performance to standard of care and competitive technologies in India
- Recommend feature prioritization based on impact for home users

#### 3.4.2 Technical Performance Review
- Evaluate BCI signal acquisition and processing performance in typical Indian home environments
- Assess exoskeleton mechanical performance and safety for daily use
- Review human factors and usability testing results with Indian users
- Provide feedback on user interface design for the Indian market
- Evaluate algorithm performance and adaptation capabilities for long-term home use

#### 3.4.3 Innovation Guidance
- Identify unmet clinical needs in the Indian market for future development
- Recommend technology enhancements based on Indian user experience
- Advise on integration with complementary technologies available in India
- Guide development of next-generation features for the Indian market
- Provide insights on emerging competitive technologies in India

### 3.5 Knowledge Dissemination

#### 3.5.1 Publication Strategy
- Guide development of publication plan for clinical results from Indian studies
- Review key manuscripts prior to submission
- Recommend target journals and conferences in India and internationally
- Advise on addressing reviewer comments
- Support development of white papers and review articles for the Indian medical community

#### 3.5.2 Patient and Caregiver Education
- Guide development of training materials for patients and caregivers
- Advise on home use training programs
- Support creation of patient education materials in multiple Indian languages
- Recommend approaches for community engagement in India
- Provide guidance on patient education initiatives

#### 3.5.3 Stakeholder Engagement
- Facilitate connections with key opinion leaders in Indian healthcare
- Support engagement with patient advocacy organizations in India
- Advise on payer and health system education in the Indian context
- Guide development of value proposition messaging for the Indian market
- Support engagement with professional societies in India

## 4. Membership Composition

### 4.1 Expertise Requirements

The CAB consists of 7-9 members representing diverse expertise relevant to brain-controlled exoskeletons for home use in India:

<div align="center">
<img src="https://mermaid.ink/img/pako:eNp1kk9PwzAMxb9KlBOI9QvkMG3qBBJiB8QOvUQmMY3WJlWSMjZV_e7YbVlhwJf4-fez_OzCuJUEBbwQb8lYvGvDLZIVUXxA8t5ZJA_WkVYRXdA6JGQvVkWUhLxGRWQMqQhXZJV3pCNcxHmcx1mcx_9i5_uoI1zGeZzHeZzH-b_YRYRXcR7ncR7ncR7nMXZ-jjrCdZzHeZzHeZzHeYyd36KO8C7O4zzO4zzO4zzGzh9RR_gY53Ee53Ee53EeY-fPqCP8ivM4j_M4j_M4j7HzLuoIf-I8zuM8zuM8zmPs_Bt1hMc4j_M4j_M4j_MYO0-ijvAU53Ee53Ee53EeY-c0wlOcx3mcx3mcx3mMnbMIT3Ee53Ee53Ee5zF2ziM8xXmcx3mcx3mcx9i5iPAU53Ee53Ee53EeY-cywnOcx3mcx3mcx3mMnasIz3Ee53Ee53Ee5zF2riO8xHmcx3mcx3mcx9i5ifAS53Ee53Ee53EeY-c2wkucx3mcx3mcx3mMnbsIL3Ee53Ee53Ee5zF27iO8xnmcx3mcx3mcx9h5iPAa53Ee53Ee53EeY-cxwmucx3mcx3mcx3mMnacIb3Ee53Ee53Ee5zF2niO8xXmcx3mcx3mcx9h5ifAW53Ee53Ee53EeY-c1wlucx3mcx3mcx3mMnbcI73Ee53Ee53Ee5zF23iO8x3mcx3mcx3mcx9j5iPAe53Ee53Ee53EeY-czwnucx3mcx3mcx3mMna8IH3Ee53Ee53Ee5zF2viN8xHmcx3mcx3mcx9j5ifAR53Ee53Ee53EeY-e_CB9xHudxHudxHucxdv4HxvXwKQ?type=png" alt="Advisory Board Expertise Map" width="700px" />
</div>

<table>
<tr>
<th>Expertise Area</th>
<th>Required Experience</th>
<th>Key Responsibilities</th>
<th>Number of Members</th>
</tr>
<tr>
<td><strong>Neurology (India)</strong></td>
<td>
• Expertise in motor neuron diseases, spinal cord injury, or stroke rehabilitation<br>
• Experience with neurological rehabilitation in India<br>
• Medical Council of India registration<br>
• Minimum 10 years clinical practice in India<br>
• Publication record in relevant areas
</td>
<td>
• Lead clinical protocol development for Indian patients<br>
• Evaluate neurological safety aspects for home use<br>
• Guide patient selection criteria for the Indian population<br>
• Advise on neurological outcome measures<br>
• Support regulatory neurological assessments for CDSCO
</td>
<td align="center">1-2</td>
</tr>
<tr>
<td><strong>Physical Medicine and Rehabilitation (India)</strong></td>
<td>
• Expertise in rehabilitation medicine in India<br>
• Experience with assistive technologies in Indian healthcare settings<br>
• Medical Council of India registration<br>
• Minimum 8 years clinical practice in India<br>
• Experience in rehabilitation technology implementation
</td>
<td>
• Guide home rehabilitation protocol development<br>
• Advise on functional outcome measures for Indian patients<br>
• Evaluate usability in Indian home settings<br>
• Develop patient and caregiver training requirements<br>
• Support reimbursement strategy for the Indian market
</td>
<td align="center">1-2</td>
</tr>
<tr>
<td><strong>Neuroscience/Neurophysiology</strong></td>
<td>
• Expertise in EEG signal processing and interpretation<br>
• Understanding of motor control and neural plasticity<br>
• PhD in neuroscience or related field<br>
• Research experience with BCI technology<br>
• Publication record in neural signal processing<br>
• Experience with Indian research institutions preferred
</td>
<td>
• Evaluate BCI algorithm performance in diverse environments<br>
• Guide signal processing improvements for home use<br>
• Advise on neuroplasticity considerations<br>
• Support technical performance assessment<br>
• Guide development of novel BCI approaches for unsupervised use
</td>
<td align="center">1</td>
</tr>
<tr>
<td><strong>Bioethics (India)</strong></td>
<td>
• Expertise in neuroethics and emerging technologies<br>
• Experience with ethics committees in India<br>
• Formal training in bioethics<br>
• Publication record in ethics<br>
• Experience with ethics committees in India<br>
• Understanding of Indian cultural and ethical considerations
</td>
<td>
• Develop ethical framework for technology use in India<br>
• Guide informed consent processes for Indian patients<br>
• Advise on privacy protections for neural data under Indian law<br>
• Address equity and access considerations in the Indian context<br>
• Support responsible innovation practices
</td>
<td align="center">1</td>
</tr>
<tr>
<td><strong>Patient Advocacy (India)</strong></td>
<td>
• Representative from relevant patient community in India<br>
• Experience in patient-centered research design<br>
• Connection to patient advocacy organizations in India<br>
• Understanding of lived experience with mobility impairment<br>
• Experience in patient advisory roles in India
</td>
<td>
• Ensure Indian patient perspective in development<br>
• Guide development of patient-reported outcomes relevant to Indian users<br>
• Advise on user experience considerations for Indian home environments<br>
• Support patient recruitment strategies in India<br>
• Facilitate connections with patient communities across India
</td>
<td align="center">1</td>
</tr>
<tr>
<td><strong>Regulatory Affairs (India)</strong></td>
<td>
• Experience with CDSCO medical device approval processes<br>
• Knowledge of Medical Devices Rules, 2017<br>
• Regulatory certification preferred<br>
• Minimum 8 years in regulatory affairs in India<br>
• Experience with Class C medical device submissions to CDSCO
</td>
<td>
• Guide CDSCO regulatory strategy development<br>
• Advise on regulatory submission content for India<br>
• Support preparation for CDSCO meetings<br>
• Provide insights on international regulations for expansion<br>
• Advise on post-market requirements in India
</td>
<td align="center">1</td>
</tr>
<tr>
<td><strong>Home Healthcare Expert (India)</strong></td>
<td>
• Expertise in home healthcare delivery in India<br>
• Experience with medical devices used in home settings<br>
• Understanding of Indian home environments and challenges<br>
• Experience training patients and caregivers<br>
• Knowledge of remote monitoring technologies
</td>
<td>
• Design home use protocols for Indian settings<br>
• Develop caregiver training programs<br>
• Advise on home environment adaptations<br>
• Guide remote monitoring implementation<br>
• Support home use safety strategies
</td>
<td align="center">1</td>
</tr>
<tr>
<td><strong>Clinical Research Methodology</strong></td>
<td>
• Expertise in clinical trial design and biostatistics<br>
• Experience with medical device clinical studies in India<br>
• PhD in biostatistics, epidemiology, or related field<br>
• Publication record in clinical research methods<br>
• Experience with adaptive trial designs<br>
• Knowledge of Indian clinical research regulations
</td>
<td>
• Design statistically rigorous clinical trials for Indian studies<br>
• Develop data analysis plans<br>
• Advise on sample size and power calculations<br>
• Guide interim analysis approaches<br>
• Support clinical evidence synthesis
</td>
<td align="center">1</td>
</tr>
<tr>
<td><strong>International Regulatory Expert</strong> (Optional)</td>
<td>
• Experience with FDA medical device approval processes<br>
• Knowledge of Software as a Medical Device (SaMD) regulations<br>
• RAC certification preferred<br>
• Minimum 8 years in regulatory affairs<br>
• Experience with Class II/III medical device submissions to FDA
</td>
<td>
• Provide guidance on FDA regulatory pathways<br>
• Advise on international regulatory strategy<br>
• Support preparation for FDA meetings when appropriate<br>
• Guide harmonization between Indian and international requirements<br>
• Advise on global expansion strategy
</td>
<td align="center">0-1</td>
</tr>
</table>

### 4.2 Member Selection Criteria

Members will be selected based on the following criteria:

1. **Professional Qualifications**: Demonstrated expertise in relevant field with appropriate credentials
2. **Industry Recognition**: Standing as a key opinion leader or recognized expert in India
3. **Research Contributions**: Publication record and research impact in relevant areas
4. **Clinical Experience**: Direct experience with relevant patient populations or technologies in Indian healthcare settings
5. **Regulatory Knowledge**: Understanding of regulatory requirements for medical devices in India
6. **Collaborative Approach**: Demonstrated ability to work effectively in advisory roles
7. **Diversity Considerations**: Representation across gender, geography, and professional backgrounds
8. **Conflict Management**: Ability to manage potential conflicts of interest appropriately

### 4.3 Diversity and Inclusion

The CAB will prioritize diversity across multiple dimensions:

- **Gender Balance**: Minimum 40% representation of any gender
- **Geographic Diversity**: Representation from multiple regions across India
- **Institutional Diversity**: Members from academic, clinical, industry, and advocacy settings
- **Perspective Diversity**: Inclusion of varied viewpoints and approaches
- **Career Stage Diversity**: Mix of established leaders and emerging experts
- **Linguistic Diversity**: Representation of major Indian languages to support patient education materials

## 5. Current Advisory Board Members

<table>
<tr>
<th>Name</th>
<th>Expertise</th>
<th>Institution</th>
<th>Term</th>
</tr>
<tr>
<td>Dr. Rajesh Sharma</td>
<td>Neurology</td>
<td>All India Institute of Medical Sciences, New Delhi</td>
<td>2 years (2025-2027)</td>
</tr>
<tr>
<td>Dr. Priya Venkatesh</td>
<td>Physical Medicine and Rehabilitation</td>
<td>Christian Medical College, Vellore</td>
<td>2 years (2025-2027)</td>
</tr>
<tr>
<td>Dr. Amit Patel</td>
<td>Neuroscience/Neurophysiology</td>
<td>Indian Institute of Science, Bangalore</td>
<td>2 years (2025-2027)</td>
</tr>
<tr>
<td>Dr. Lakshmi Krishnan</td>
<td>Bioethics</td>
<td>Tata Institute of Social Sciences, Mumbai</td>
<td>1 year (2025-2026)</td>
</tr>
<tr>
<td>Mr. Vikram Singh</td>
<td>Patient Advocacy</td>
<td>Indian Spinal Injury Centre Patient Association</td>
<td>1 year (2025-2026)</td>
</tr>
<tr>
<td>Ms. Deepa Mehta</td>
<td>Regulatory Affairs</td>
<td>Former CDSCO Official, Independent Consultant</td>
<td>2 years (2025-2027)</td>
</tr>
<tr>
<td>Dr. Sanjay Kumar</td>
<td>Home Healthcare Expert</td>
<td>Portea Medical, Bangalore</td>
<td>1 year (2025-2026)</td>
</tr>
<tr>
<td>Dr. Ananya Gupta</td>
<td>Clinical Research Methodology</td>
<td>Post Graduate Institute of Medical Education and Research, Chandigarh</td>
<td>1 year (2025-2026)</td>
</tr>
<tr>
<td>Dr. Robert Chen</td>
<td>International Regulatory Expert</td>
<td>Former FDA Medical Device Reviewer, Global Regulatory Consultants</td>
<td>1 year (2025-2026)</td>
</tr>
</table>

## 6. Operational Procedures

### 6.1 Meeting Schedule and Format

- **Regular Meetings**: Quarterly (4 per year)
- **Special Meetings**: As needed for urgent matters
- **Format**: Hybrid (in-person and virtual) with at least one in-person meeting annually
- **Location**: Rotating between major Indian cities (Delhi, Mumbai, Bangalore, Chennai)
- **Duration**: Regular meetings 4 hours; special meetings as required
- **Attendance Requirement**: 75% of meetings annually

### 6.2 Meeting Procedures

- **Agenda Development**
  - Draft agenda distributed 3 weeks before meeting
  - Members may suggest agenda items up to 2 weeks before meeting
  - Final agenda distributed 1 week before meeting
  - Standing agenda items include safety updates, regulatory developments, and clinical progress

- **Meeting Materials**
  - Distributed at least 1 week before meeting
  - Pre-read materials clearly identified
  - Confidentiality maintained for all materials

- **Meeting Conduct**
  - Chaired by CAB Chairperson
  - Structured discussion with equal opportunity for input
  - Formal recommendations documented
  - Voting when necessary (simple majority)

- **Documentation**
  - Minutes prepared within 1 week
  - Review and approval of minutes by members
  - Action items tracked with owners and deadlines
  - Formal recommendations documented with rationale

### 6.3 Decision-Making Process

- **Consensus Approach**: Seek consensus when possible
- **Voting Procedures**: Simple majority when consensus not reached
- **Recommendation Documentation**: Formal documentation of all recommendations
- **Dissenting Opinions**: Recorded in meeting minutes when requested
- **Escalation Process**: Clear pathway for urgent matters between meetings

### 6.4 Subcommittees

The CAB may establish subcommittees for specific focus areas:

1. **Clinical Trial Subcommittee**
   - Oversees clinical study design and execution
   - Reviews clinical protocols in detail
   - Monitors study progress
   - Evaluates clinical results

2. **Home Use Safety Subcommittee**
   - Focuses on safety for unsupervised home use
   - Reviews adverse events
   - Develops risk mitigation strategies
   - Evaluates home use protocols

3. **Regulatory Strategy Subcommittee**
   - Guides CDSCO submission strategy
   - Reviews regulatory documentation
   - Monitors regulatory developments
   - Prepares for regulatory meetings

4. **Ethics and Patient Engagement Subcommittee**
   - Addresses ethical considerations
   - Ensures patient perspective integration
   - Reviews informed consent processes
   - Guides patient education materials

5. **International Expansion Subcommittee** (when appropriate)
   - Focuses on international regulatory strategy
   - Guides harmonization between Indian and international requirements
   - Advises on adaptation for international markets
   - Supports preparation for international submissions

## 7. Compensation and Support

### 7.1 Compensation Structure

<table>
<tr>
<th>Activity</th>
<th>Compensation Rate (INR)</th>
<th>Notes</th>
</tr>
<tr>
<td>Quarterly Meetings</td>
<td>₹50,000 per meeting</td>
<td>Pro-rated for partial attendance</td>
</tr>
<tr>
<td>Special Meetings</td>
<td>₹12,500 per hour</td>
<td>Minimum 1 hour</td>
</tr>
<tr>
<td>Document Review</td>
<td>₹25,000 per review cycle</td>
<td>Based on standard document package</td>
</tr>
<tr>
<td>Subcommittee Service</td>
<td>₹25,000 per quarter</td>
<td>Per subcommittee</td>
</tr>
<tr>
<td>Annual Retainer</td>
<td>₹200,000</td>
<td>Paid quarterly</td>
</tr>
</table>

### 7.2 Reimbursement Policy

- **Travel Expenses**: Reimbursed according to Chimera travel policy
  - Business class air travel for flights over 3 hours
  - 5-star hotel accommodations
  - Ground transportation
  - Meals and incidentals per company policy

- **Documentation Required**
  - Original receipts for all expenses
  - Completed expense report form
  - Submission within 30 days of expense

### 7.3 Administrative Support

- **Dedicated Coordinator**: Assigned to manage CAB operations
- **Meeting Support**: Logistics, materials, minutes
- **Document Management**: Distribution and version control
- **Communication**: Regular updates between meetings
- **Expense Processing**: Timely reimbursement and honoraria payment

## 8. Confidentiality and Intellectual Property

### 8.1 Confidentiality Requirements

- **Confidentiality Agreement**: All members must sign comprehensive agreement
- **Material Handling**: Secure handling of all confidential materials
- **Discussion Limitations**: No external discussion of confidential matters
- **Duration**: Obligations extend 5 years beyond CAB service
- **Return of Materials**: All confidential materials returned upon term completion

### 8.2 Intellectual Property

- **Ownership**: All IP generated through CAB activities belongs to Chimera
- **Assignment**: Members assign all rights to relevant IP
- **Disclosure**: Obligation to disclose potentially patentable ideas
- **Prior IP**: Clear documentation of pre-existing IP
- **Publications**: Review process for CAB-related publications

### 8.3 Conflict of Interest Management

- **Disclosure Requirement**: Annual and ad-hoc disclosure of potential conflicts
- **Review Process**: Evaluation of disclosed conflicts
- **Management Plans**: Development of specific management plans when needed
- **Recusal**: Recusal from discussions with direct conflicts
- **Ongoing Monitoring**: Regular review of potential new conflicts

## 9. Reporting and Accountability

### 9.1 Reporting Structure

<div align="center">
<img src="https://mermaid.ink/img/pako:eNp1kk9PwzAMxb9KlBOI9QvkMG3qBBJiB8QOvUQmMY3WJlWSMjZV_e7YbVlhwJf4-fez_OzCuJUEBbwQb8lYvGvDLZIVUXxA8t5ZJA_WkVYRXdA6JGQvVkWUhLxGRWQMqQhXZJV3pCNcxHmcx1mcx_9i5_uoI1zGeZzHeZzH-b_YRYRXcR7ncR7ncR7nMXZ-jjrCdZzHeZzHeZzHeYyd36KO8C7O4zzO4zzO4zzGzh9RR_gY53Ee53Ee53EeY-fPqCP8ivM4j_M4j_M4j7HzLuoIf-I8zuM8zuM8zmPs_Bt1hMc4j_M4j_M4j_MYO0-ijvAU53Ee53Ee53EeY-c0wlOcx3mcx3mcx3mMnbMIT3Ee53Ee53Ee5zF2ziM8xXmcx3mcx3mcx9i5iPAU53Ee53Ee53EeY-cywnOcx3mcx3mcx3mMnasIz3Ee53Ee53Ee5zF2riO8xHmcx3mcx3mcx9i5ifAS53Ee53Ee53EeY-c2wkucx3mcx3mcx3mMnbsIL3Ee53Ee53Ee5zF27iO8xnmcx3mcx3mcx9h5iPAa53Ee53Ee53EeY-cxwmucx3mcx3mcx3mMnacIb3Ee53Ee53Ee5zF2niO8xXmcx3mcx3mcx9h5ifAW53Ee53Ee53EeY-c1wlucx3mcx3mcx3mMnbcI73Ee53Ee53Ee5zF23iO8x3mcx3mcx3mcx9j5iPAe53Ee53Ee53EeY-czwnucx3mcx3mcx3mMna8IH3Ee53Ee53Ee5zF2viN8xHmcx3mcx3mcx9j5ifAR53Ee53Ee53EeY-e_CB9xHudxHudxHucxdv4HxvXwKQ?type=png" alt="CAB Reporting Structure" width="700px" />
</div>

<table border="1" cellpadding="5" cellspacing="0" width="100%">
<tr bgcolor="#E6E6FA">
<th>Reporting Entity</th>
<th>Frequency</th>
<th>Format</th>
<th>Key Content</th>
</tr>
<tr>
<td><strong>CAB Chair → CEO</strong></td>
<td>Monthly</td>
<td>Executive Brief</td>
<td>Strategic recommendations, critical issues, high-level progress</td>
</tr>
<tr>
<td><strong>CAB → Chief Medical Officer</strong></td>
<td>Bi-weekly</td>
<td>Detailed Report</td>
<td>Clinical guidance, regulatory strategy, safety monitoring</td>
</tr>
<tr>
<td><strong>CAB → Board of Directors</strong></td>
<td>Quarterly</td>
<td>Presentation</td>
<td>Strategic impact, regulatory milestones, risk assessment</td>
</tr>
<tr>
<td><strong>Subcommittees → CAB</strong></td>
<td>Monthly</td>
<td>Status Report</td>
<td>Focused recommendations, action items, progress updates</td>
</tr>
<tr>
<td><strong>CAB → Functional Teams</strong></td>
<td>As needed</td>
<td>Guidance Document</td>
<td>Specific technical or clinical recommendations</td>
</tr>
</table>

### 9.2 Performance Metrics

The CAB's performance will be evaluated based on:

1. **Meeting Participation**: Attendance and engagement
2. **Recommendation Quality**: Actionability and impact of guidance
3. **Regulatory Impact**: Contribution to regulatory success
4. **Clinical Guidance**: Quality of clinical protocol input
5. **Strategic Value**: Contribution to strategic direction
6. **Knowledge Contribution**: Specific expertise application
7. **Responsiveness**: Timeliness of input and reviews

### 9.3 Annual Review Process

- **Self-Assessment**: CAB completes annual self-evaluation
- **Company Assessment**: Executive team evaluates CAB performance
- **Individual Assessments**: Evaluation of individual member contributions
- **Feedback Session**: Structured feedback on performance
- **Improvement Planning**: Development of specific improvement actions

## 10. Charter Management

### 10.1 Charter Review and Updates

- **Annual Review**: Formal review of charter annually
- **Amendment Process**: Proposed changes reviewed by CAB and approved by Board of Directors
- **Version Control**: Clear documentation of all changes
- **Distribution**: Updated charter distributed to all members

### 10.2 Charter Governance

- **Ownership**: Chief Medical Officer
- **Approval Authority**: Board of Directors
- **Implementation Responsibility**: CAB Chair
- **Compliance Monitoring**: Corporate Secretary

## 11. Conclusion

This charter establishes a comprehensive framework for the Chimera Clinical Advisory Board to provide expert guidance on the development, validation, and implementation of our brain-controlled exoskeleton technology for home use without professional supervision in India. By leveraging the expertise of leading Indian healthcare professionals, the CAB will play a critical role in ensuring our technology meets the highest standards of safety, efficacy, and ethical implementation while navigating the Indian regulatory landscape efficiently.

The CAB represents a strategic investment in clinical and regulatory excellence that will accelerate our path to market and support our billion-dollar funding goals by demonstrating our commitment to world-class clinical validation and responsible innovation in the Indian healthcare technology sector.

## 12. FDA Annexure: International Regulatory Considerations

### 12.1 FDA Regulatory Pathway

For future international expansion, the CAB will provide guidance on the following FDA regulatory considerations:

- **Device Classification**: Powered exoskeleton (Product Code: PHL) is typically a Class II device requiring 510(k) clearance
- **De Novo Pathway**: Novel BCI components may require De Novo classification
- **Software as a Medical Device (SaMD)**: BCI software components will be evaluated under FDA's SaMD framework
- **Pre-Submission Program**: Strategic use of FDA's Pre-Submission program for early feedback
- **Clinical Evidence Requirements**: Design of clinical studies that satisfy both CDSCO and FDA requirements
- **Quality System Regulation**: Implementation of 21 CFR Part 820 requirements alongside MDR 2017 compliance

### 12.2 Harmonization Strategy

The CAB will advise on harmonization between Indian and international requirements:

- **Standards Alignment**: Adoption of internationally recognized standards (ISO, IEC) that satisfy both CDSCO and FDA
- **Clinical Protocol Design**: Development of clinical protocols that generate evidence acceptable to multiple regulatory authorities
- **Quality Management System**: Implementation of a unified quality system that meets requirements of multiple jurisdictions
- **Risk Management**: Adoption of ISO 14971 approach acceptable to both CDSCO and FDA
- **Technical Documentation**: Creation of technical documentation that can be leveraged across regulatory submissions

### 12.3 International Clinical Strategy

For potential international expansion, the CAB will provide guidance on:

- **Clinical Investigation Planning**: Design of clinical studies that can support both Indian and international regulatory submissions
- **Site Selection Strategy**: Identification of clinical sites with experience in multinational studies
- **Data Collection Harmonization**: Implementation of consistent data collection methods across regions
- **Statistical Analysis Planning**: Development of statistical approaches that satisfy multiple regulatory authorities
- **Post-Market Study Design**: Creation of post-market surveillance plans that meet global requirements

### 12.4 Global Standards Compliance

The CAB will advise on compliance with international standards including:

- **ISO 13485:2016**: Medical devices — Quality management systems
- **ISO 14971:2019**: Medical devices — Application of risk management to medical devices
- **IEC 62304:2015**: Medical device software — Software life cycle processes
- **IEC 62366-1:2015**: Medical devices — Application of usability engineering to medical devices
- **ISO 14155:2020**: Clinical investigation of medical devices for human subjects
- **IEC 60601-1**: Medical electrical equipment safety standards

---

<div align="center">
<p><strong>Document Control</strong></p>

| Version | Date | Author | Changes |
|---------|------|--------|---------|
| 1.0 | April 16, 2025 | Chimera Clinical Team | Initial version (FDA focus) |
| 2.0 | April 16, 2025 | Chimera Clinical Team | Enhanced version with improved structure |
| 3.0 | April 17, 2025 | Chimera Clinical Team | Updated for Indian regulations and home use |
| 4.0 | April 18, 2025 | Chimera Clinical Team | Unified version with FDA annexure while maintaining Indian focus |

<p><em>This document is confidential and proprietary to Chimera. It may not be reproduced or distributed without permission.</em></p>
</div>
